Notable
KST-6051 · Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Primary completion pushed from Jun 2027 to Apr 2028
Also in this update: Primary endpoint(s) modified; Enrollment increased: 145 → 545 participants
Kestrel Therapeutics, Inc.Phase 1 NCT07458347 Registry history of NCT07458347 on ClinicalTrials.gov (opens the registry)